Ramipril therapy in the framework of evidence-based medicine
https://doi.org/10.18705/1607-419X-2009-15-2-242-245
Abstract
The article summarizes the available data on ramipril in hypertensive patients of high cardiovascular risk. The results
of studies demonstrate strong and long-lasting antihypertensive effect of ramipril. Moreover, ramipril treatment decreases
cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. The
treatment by ramipril represents vasculoprotective and renoprotective effects in diabetes patients. Possible antiarrhythmic
activity of ramipril is of particular interest in atrial fi brillation. Ramipril shows both high effi cacy and low adverse event
rate. All this properties make ramipril extremely attractive for the everyday practice.
of studies demonstrate strong and long-lasting antihypertensive effect of ramipril. Moreover, ramipril treatment decreases
cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. The
treatment by ramipril represents vasculoprotective and renoprotective effects in diabetes patients. Possible antiarrhythmic
activity of ramipril is of particular interest in atrial fi brillation. Ramipril shows both high effi cacy and low adverse event
rate. All this properties make ramipril extremely attractive for the everyday practice.
About the Authors
N. Goncharova
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
O. M. Moiseeva
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
References
1. Kannel W. Blood pressure as a cardiovascular risk factor: prevention and treatment // JAMA. - 1996. - Vol. 275. - P. 1571-1576.
2.
3. Kaplan N., Sproul L., Mulcahy W. Large prospective study of ramipril in patients with hypertension. CARE Investigators // Clin. Ther. - 1993. - Vol. 15, № 5. - P. 810-818.
4.
5. MacMahon S., Peto R., Cutler J. et al. Blood pressure stroke coronary heart disease. Part I prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias // Lancet. - 1990. - Vol. 35. - P. 765-774.
6.
7. Ezzati M., Lopez A., Rodreges A. et al. Comparative Risk Assessment Collaboration Group. Selected major risk factors and global and regional burden of disease // Lancet. - 2002. - Vol. 360. - P. 1347-1360.
8.
9. ESC 2007 Guidelines for the management of arterial hypertension // Eur. Heart J. - 2007. - Vol. 28. - P. 1462-1536.
10.
11. Williams B., Gosse P., Lowe L., Harper R. PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I) // J. Hypertens. - 2006. - Vol. 24, № 1. - P. 193-200.
12.
13. Frampton J., Peters D. Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure // Drugs. - 1995. - Vol. 49, № 3. - P. 440-446.
14.
15. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // Lancet. - 2000. - Vol. 355, № 9200. - P. 253-259.
16.
17. Spargias K., Ball S., Hall A. The prognostic significance of a history of systemic hypertension in patients randomized to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy // J. Hum. Hypertens. - 1999. - Vol. 13, № 8. - P. 511-516.
18.
19. Wienbergen H ., Schiele R ., Gitt A . et al. MITRA PLUS Study Group Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction // Am. J. Cardiol. - 2002. - Vol. 90, № 10. - P. 1045-1049.
20.
21. Kjøller-Hansen L., Steffensen R., Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES) // J. Am. Coll. Cardiol. - 2000. - Vol. 35, № 4. - P. 881-888.
22.
23. Yusuf S., Gerstein H., Hoogwerf B. et al. HOPE Study Investigators. Ramipril and the development of diabetes // JAMA. - 2001. - Vol. 286, № 15. - P. 882-1885.
24.
25. Bosch J., Yusuf S., Gerstein H. et al. DREAM Trial Investigators. Effect of ramipril on theincidence of diabetes // N. Engl. J. Med. - 2006. - Vol. 355, № 15. - P. 1551-1562.
26.
27. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation) // J. Renin Angiotensin Aldosterone Syst. - 2000. - Vol. 1. - P. 18-20.
28.
29. Bosch J., Lonn E., Poque J. et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension // Circulation. - 2005. - Vol. 112, № 9. - P. 1339-1346.
30.
31. Marre M ., Lievre M ., Chatellier G . et al. DIABHYCAR Study Investigators Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) // ----Curr. Hypertens. Rep. 2004. Vol. 6, № 5. P. 366368.
32.
33. Ruggenenti P., Perna A., Ghererdi G. et al. Renal function and rrequirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial // Lancet. - 1998. - Vol. 352. - P. 1252-1256.
34.
35. Belluzzi F., Sernesi L., Preti P. et al. Prevention of Recurrent Lone Atrial Fibrillation by the Angiotensin-II Converting Enzyme Inhibitor Ramipril in Normotensive Patients // J. Am. Coll. Cardiol. - 2009. - Vol. 53. - P. 24-29.
36.
37. Diet F., Pratt R., Berry G. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease // Circulation. - 1996. - Vol. 94. - P. 2756-2767.
38.
39. Chobanian A., Haudenschild C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit // Hypertension. - 1990. - Vol. 15. - P. 327-331.
40.
41. Lonn E . Modifying the natural history of atherosclerosis: the SECURE trial // Int. J. Clin. Pract. Suppl. - 2001. - № 117. - P. 13-18.
42.
43. Fukuda D , Enomoto S ., Nagai R ., Sata M . Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation // Biomed Pharmacother. - 2009. [Электронный ресурс] doi:10.1016/j.biopha.2009.02.006
44.
45. Lonn E., Yusuf S., Dzavik V. et al. the SECURE Study Investigators. Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) // Circulation. - 2001. - Vol. 103. - P. 919-925.
46.
47. Agabiti-Rosei E., Ambrosioni E., Dal Palu C. et al. on behalf of the RACE Study Group ACE inhibitor ramipril is more effective than the b-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study // J. Hypertens. - 1995. - Vol. 13. - P. 1325-1334.
48.
49. Lievre M., Gueret P., Gayet C. et al. on behalf of the HYCAR Study Group Ramipril-Induced Rgression of the Left Ventricular Hypertrophy in Treated Hypertensive Individuals // Hypertension. - 1995. - Vol. 25. - P. 92-97.
50.
Review
For citations:
Goncharova N., Moiseeva O.M. Ramipril therapy in the framework of evidence-based medicine. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(2):242-245. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-2-242-245
Views:
1029
Email this article 